The survival after discontinuation of EGFR‐TKIs due to intolerable adverse events in patients with EGFR‐mutated non–small cell lung cancer

BACKGROUND: Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are standard treatments for advanced non–small cell lung cancer (NSCLC) patients harboring the EGFR mutation. Patients experiencing intolerable adverse events (AEs) would discontinue EGFR‐TKIs. This study aimed to ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, John Wen‐Cheng, Chang, Ching‐Fu, Huang, Chen‐Yang, Yang, Cheng‐Ta, Kuo, Chih‐Hsi Scott, Fang, Yueh‐Fu, Hsu, Ping‐Chih, Wu, Chiao‐En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891857/
https://www.ncbi.nlm.nih.gov/pubmed/36525509
http://dx.doi.org/10.1111/1759-7714.14674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891857/
https://www.ncbi.nlm.nih.gov/pubmed/36525509
http://dx.doi.org/10.1111/1759-7714.14674

Ejemplares similares